Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.

Employees

Sector

Investment Holding Companies

More about the company

Quotes

Date	Price	Change	Volume
26-08-05	$1.640	0.00%	20,686
26-08-04	$1.640	+1.86%	287,435
26-07-31	$1.610	+3.21%	104,233
26-07-30	$1.560	+2.63%	317,489
26-07-29	$1.520	-5.00%	551,417

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Toronto S.E. Other stock markets 15:59:33 2026-08-05 EDT			5-day change	1st Jan Change
1.640 ^CAD	0.00%		+7.89%	+3,180.00%

07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI

Market Cap	183M 158M 148M 136M 256M 17.39B 259M 1.74B 681M 8.7B 687M 672M 28.82B	P/E 2024 *	-	P/E 2025	-0.29x
Enterprise Value	180M 156M 145M 134M 252M 17.12B 255M 1.71B 670M 8.57B 676M 661M 28.37B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	79.62%	Yield 2024 *	-	Yield 2025	-

07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization	MT
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
07-17	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
07-15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
07-08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
07-07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
06-30	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI
06-12	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform	CI
06-08	Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors	CI
05-13	Vector Science and Therapeutics enters option to buy up to 15% of Lyogenesis Plus for up to $1 million	RE
05-11	Vector Science & Therapeutics Inc. Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC	CI

07-27	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-24	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-21	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
07-17	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist	AQ
07-15	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ

Vector Science and Therapeutics Corp. Stock

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Valuation: Vector Science and Therapeutics Corp.

Chart: Vector Science and Therapeutics Corp.

Latest news : Vector Science and Therapeutics Corp.

Press Releases: Vector Science and Therapeutics Corp.

Quotes and Performance

Course Extremes

Latest insider transactions

Shell Companies

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	+7.89%
Current month	+1.86%
1 month	-32.51%
3 months	+160.32%
6 months	+3,180.00%
Current year	+3,180.00%

1 week	1.51	1.65
1 month	1.46	2.48
Current year	0.35	2.65
1 year	0.35	2.65
3 years	0.03	2.65
5 years	0.03	2.65
10 years	0.03	2.65

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VECTOR SCIENCE AND THERAPEUTICS CORP.	0.00%	+7.89%	+3,180.00%	+2,633.33%	183M
BOXABL INC.	-1.93%	-8.03%	-54.06%	-	13.32B
FREENOME, INC.	+11.61%	+10.83%	+5.49%	-	1.23B
CHURCHILL CAPITAL CORP XI	+3.44%	+17.83%	-	-	887M
CENTIEL AG	+0.44%	+10.39%	+309.64%	-64.95%	685M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	644M
CHURCHILL CAPITAL CORP XII	+0.52%	+0.80%	-	-	603M
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	-0.20%	-	-	596M
CANTOR EQUITY PARTNERS IV, INC.	-0.33%	-0.52%	-	-	593M
Average	+1.53%	+5.73%	+860.27%	+1,284.19%	2.08B
Weighted average by Cap.	-0.42%	+12.75%	+5.22%	+503.58%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-